Cargando…

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

BACKGROUND: Arginine-depleting therapy with pegylated arginine deiminase (ADI-PEG20) was reported to have activity in advanced melanoma in early phase I–II trial, and clinical trials are currently underway in other cancers. However, the optimal patient population who benefit from this treatment is u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feun, L G, Marini, A, Walker, G, Elgart, G, Moffat, F, Rodgers, S E, Wu, C J, You, M, Wangpaichitr, M, Kuo, M T, Sisson, W, Jungbluth, A A, Bomalaski, J, Savaraj, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341859/ https://www.ncbi.nlm.nih.gov/pubmed/22472884 http://dx.doi.org/10.1038/bjc.2012.106

Ejemplares similares

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase
por: Kelly, M P, et al.
Publicado: (2012)

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
por: Savaraj, Niramol, et al.
Publicado: (2015)

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
por: Savaraj, Niramol, et al.
Publicado: (2007)

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
por: Beddowes, Emma, et al.
Publicado: (2017)

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis
por: Delage, B, et al.
Publicado: (2012)

Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy
por: McAlpine, Jennifer A, et al.
Publicado: (2014)

Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism
por: Zhang, Yiming, et al.
Publicado: (2022)

The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma
por: Thongkum, Angkana, et al.
Publicado: (2017)

RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells
por: Wu, Fe-Lin Lin, et al.
Publicado: (2011)

Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth
por: Park, I-S, et al.
Publicado: (2003)

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling
por: Liu, Jiangbo, et al.
Publicado: (2014)

Pegylated Arginine Deiminase Downregulates Colitis in Murine Models
por: Oz, Helieh S., et al.
Publicado: (2012)

PEGylation increases antitumoral activity of arginine deiminase of Streptococcus pyogenes
por: Schwarz, Rico, et al.
Publicado: (2021)

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
por: Li, Ying-Ying, et al.
Publicado: (2016)

Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
por: Wu, Chunjing, et al.
Publicado: (2021)

Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
por: Kim, Stephanie S., et al.
Publicado: (2020)

Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer
por: Daylami, Rouzbeh, et al.
Publicado: (2014)

Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes
por: Kuo, Macus Tien, et al.
Publicado: (2010)

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma
por: Syed, N, et al.
Publicado: (2013)

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
por: Chang, Kwang-Yu, et al.
Publicado: (2021)

Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines
por: Shan, Yan-Shen, et al.
Publicado: (2015)

Arginine Depletion by Arginine Deiminase Does Not Affect Whole Protein Metabolism or Muscle Fractional Protein Synthesis Rate in Mice
por: Marini, Juan C., et al.
Publicado: (2015)

Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation
por: Li, Ying‐Ying, et al.
Publicado: (2017)

Arginine metabolism and the role of arginine deiminase-producing microorganisms in kimchi fermentation
por: Jung, Sera, et al.
Publicado: (2022)

Depletion of Arginine by Recombinant Arginine Deiminase Induces nNOS-Activated Neurotoxicity in Neuroblastoma Cells
por: Lin, Shan-Erh, et al.
Publicado: (2014)

Argininosuccinate synthase 1, arginine deprivation therapy and cancer management
por: Sun, Naihui, et al.
Publicado: (2022)

Streptococcal Arginine Deiminase Inhibits T Lymphocyte Differentiation In Vitro
por: Starikova, Eleonora A., et al.
Publicado: (2023)

A protocol to induce systemic autophagy and increase energy metabolism in mice using PEGylated arginine deiminase
por: Zhang, Yiming, et al.
Publicado: (2022)

Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas
por: Cheon, Dong‐Joo, et al.
Publicado: (2014)

Targeting the Proline–Glutamine–Asparagine–Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy
por: Kuo, Macus Tien, et al.
Publicado: (2021)

Multilevel Approach for the Treatment of Giardiasis by Targeting Arginine Deiminase
por: Fernández-Lainez, Cynthia, et al.
Publicado: (2021)

Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20)
por: Burrows, Natalie, et al.
Publicado: (2016)

Convergent evolution of the arginine deiminase pathway: the ArcD and ArcE arginine/ornithine exchangers
por: Noens, Elke E. E., et al.
Publicado: (2016)

Peptidyl Arginine Deiminase 2 (PADI2)-Mediated Arginine Citrullination Modulates Transcription in Cancer
por: Beato, Miguel, et al.
Publicado: (2020)

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
por: Yang, T-S, et al.
Publicado: (2010)

Regulation of the Arginine Deiminase System by ArgR2 Interferes with Arginine Metabolism and Fitness of Streptococcus pneumoniae
por: Schulz, Christian, et al.
Publicado: (2014)

In Vivo Targeting of Escherichia coli with Vancomycin-Arginine
por: Neville, Lewis F., et al.
Publicado: (2021)

Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation
por: Long, Yan, et al.
Publicado: (2016)

Arginine deiminase pathway enzymes: evolutionary history in metamonads and other eukaryotes
por: Novák, Lukáš, et al.
Publicado: (2016)

Discovery of Novel Potential Reversible Peptidyl Arginine Deiminase Inhibitor
por: Aliko, Ardita, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jl7jfpemnfsj5tluj0n9infap3